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Resumo
Introdução: A Síndrome de Anticorpos Antifosfo-
lípidos (SAAF) associa-se a aborto recorrente, mor-
te fetal, restrição de crescimento fetal (RCF), pre-
eclampsia, abruptio placentae, parto pretermo e
trombose materna. O tratamento com aspirina e
heparina de baixo peso molecular (HBPM) e uma
vigilância obstétrica apertada podem mudar estes
resultados.
Objectivo: Avaliar os resultados maternos e perina-
tais numa coorte de grávidas Portuguesas com
SAAF primária.
Materiais e Métodos: Análise retrospectiva de 51
grávidas com SAAF primária vigiadas na nossa ins-
tituição (Janeiro 1994 a Dezembro 2007). Quaren-
ta e uma (80,4%) apresentavam história de perdas
gestacionais, com uma taxa de filhos vivos de ape-
nas 13,79 % (16/116). Dezoito (35,3%) tinham an-
tecedentes de trombose venosa ou arterial.
Quarenta e quatro grávidas tinham anticorpos an-
ticardiolipina e 33 anticoagulante lúpico positivos.
Todas as grávidas foram medicadas com aspirina
de baixa dosagem (100 mg) e HBPM.
Resultados: Houve 67 gestações (66 simples e uma
gemelar). A taxa de filhos vivos foi de 85,1% (57/67)
com 10 perdas de gravidez: sete abortos, uma per-
da fetal tardia e duas interrupções médicas da gra-
videz (uma das quais relacionada com o SAAF). 
O peso médio (± SD) dos recém-nascidos foi de
2.837 ± 812 gr com uma idade gestacional média
de 37 semanas ± 3,3. Houve nove restrições de
crescimento fetal e 13 complicações hipertensivas
(4 síndromes HELLP). 54,4% das gestações termi-
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Abstract
Introduction: Women with antiphospholipid syn-
drome (APS) may suffer from recurrent miscar-
riage, fetal death, fetal growth restriction (FGR),
pre-eclampsia, placental abruption, premature de-
livery and thrombosis. Treatment with aspirin and
low molecular weight heparin (LMWH) combined
with close maternal-fetal surveillance can change
these outcomes.
Objective: To assess maternal and perinatal out-
come in a cohort of Portuguese women with pri-
mary APS.
Patients and Methods: A retrospective analysis of
51 women with primary APS followed in our insti-
tution (January 1994 to December 2007). Forty one
(80.4%) had past pregnancy morbidity and 35.3%
(n=18) suffered previous thrombotic events. In their
past they had a total of 116 pregnancies of which
only 13.79 % resulted in live births. Forty four pa-
tients had positive anticardiolipin antibodies and
33 lupus anticoagulant. All women received treat-
ment with low dose aspirin and LMWH.
Results: There were a total of 67 gestations (66 sin-
gle and one multiple). The live birth rate was 85.1%
(57/67) with 10 pregnancy failures: seven in the first
and second trimesters, one late fetal death and two
medical terminations of pregnancy (one APS rela-
ted). Mean (± SD) birth weight was 2837 ± 812 g
and mean gestational age 37 ± 3.3 weeks. There
were nine cases of FGR and 13 hypertensive com-
plications (4 HELLP syndromes). 54.4% of the pa-
tients delivered by caesarean section.
Conclusions: In our cohort, early treatment with
aspirin and LMWH combined with close maternal-
-fetal surveillance was associated with a very high
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nou em cesariana.
Conclusões: Na nossa população, o tratamento
precoce com aspirina e HBPM e uma vigilância
multidisciplinar associaram-se a um aumento
significativo da percentagem de filhos vivos. 
Palavras-Chave: Síndrome Anticorpos Antifosfo-
lípido Primária; Gravidez; Aspirina; Heparina de
Baixo Peso Molecular.
Introduction
Antiphospholipid syndrome (APS) is an acquired
thrombophilia characterized by the persistent pre-
sence of circulating antiphospholipid antibodies
(aPLA), associated with thromboembolic events,
pregnancy loss or both.1-4
In 1963 Bowie reported thrombosis in systemic
lupus erythematosus (SLE) patients with circula-
ting anticoagulants.5,6 Two decades later, and since
the first description by Nilsson in 1975 of a circula-
ting lupus-like anticoagulant in the plasma of wo-
men with a history of recurrent miscarriage,7
other reports enhanced this possible relationship
between pregnancy loss and antiphospholipid an-
tibodies.8,9
But it was only in 1987 that Harris and Hughes
first formalized the concept of primary Antiphos-
pholipid syndrome (PAPS) as a distinct clinical en-
tity that occurs also in individuals in absence of un-
derlying SLE or other autoimmune diseases.10
APS is clearly related to maternal morbidity. The
main obstetric-related characteristic is pregnancy
loss, namely early recurrent miscarriage and late fe-
tal death; however, several other complications
have been reported including placental insuffici-
ency leading to fetal growth restriction (FGR), pre-
eclampsia and HELLP syndrome, placental abrup-
tion, premature delivery and maternal thrombo-
sis.11 The pathogenesis of pregnancy failure and
thrombosis in APS is multifactorial, and includes
perturbations of vascular endothelium, coagulati-
on and fibrinolytic mechanisms and activation of
complement.5,12
The goal of pharmacological treatment is to pro-
tect the mother from thrombosis and reduce the
risk of fetal loss. When no specific therapy is given
during pregnancy, the rate of pregnancy loss may
be as high as 50% to 90%.13-15 In last decades seve-
ral therapeutic options including corticosteroids,
low dose aspirin, heparin and immunoglobulin
have been used either as single agents or in com-
bination in an attempt to improve the rate of live
births in these women.4,15-18 Since 1994, LMWH was
introduced in our institution, and combined with
low dose aspirin was the therapeutic option to treat
APS in pregnancy.
The aim of this study was to evaluate the outco-
me of PAPS pregnancies managed in our recurrent
miscarriage clinic.
Patients and Methods
To assess maternal and perinatal outcome of wo-
men with PAPS we performed a retrospective ana-
lysis of 51 pregnant women (mean age 31.3, SD
4.6; min 20 max 42) surveilled in our recurrent mis-
carriage clinic (January 1994 to December 2007). 
APS was diagnosed in the great majority of ca-
ses 41/51 (80.4%) during the investigation of preg-
nancy loss. All women met the accepted clinical
criteria for APS and tested positive for lupus anti-
coagulant (LA) and/or medium to high titres anti-
cardiolipin antibodies (aCL) measured on two oc-
casions at least 6 weeks apart.1, 2
Eighteen women (35.3%) had a history of throm-
bosis. Deep venous thrombosis (DVT) was the
most frequent thrombotic event (n=16). Two pa-
tients had suffered previous arterial cerebrovas-
cular accidents, and five past pulmonary throm-
boembolism. Seven of these women were on war-
farin before pregnancy. First thrombotic episode
was related to estrogen containing oral contra-
ceptives use in 8 patients, to pregnancy in two, and
plane travel in one.
Forty one (80.4%) of these women had past
pregnancy morbidity, with a total of 116 past preg-
nancies of which only 13.79% (n=16) resulted in
live births. Ten were nulligests. Twenty one patients
(42%) had a history of three or more previous preg-
nancy losses. Embryonic and fetal losses were the
most frequent type of pregnancy failure (Table I). 
Anticardiolipin antibodies (IgG and IgM) were
identified with an enzyme-linked immunosorbent
assay (ELISA) and LA was detected with a standard
activated partial thromboplastin time (aPTT) fol-
lowed by dilute Russell’s viper venom time
(dRVVT). Forty four patients (86.3%) had positive
aCL and 33 (64.7%) lupus anticoagulant. 27 tested
positive for both tests. β2 glycoprotein I antibodies
were not routinely measured until 2002. Since that
year 22 women tested positive for anti-β2 glycopro-
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oral contraceptives use was contraindicated.
Obstetric outcomes included: pregnancy loss,
the presence or absence of gestational hyperten-
sive disorders, fetal growth restriction (estimated
fetal weight below the 10th centile for gestational
age), premature delivery (before 37 weeks of ges-
tation), caesarean delivery, neonatal intensive care
unit admission, birth weight and maternal throm-
boembolism. 
Results are presented as frequencies and mean
± SD as appropriate. Fisher’s exact test was used to
compare categorical variables. For comparison
between two means an independent student’s 
t test was performed. Statistical significance was
defined as p<0.05 (SPSS version 15, Chicago IL,
USA).
Results
There were a total of 67 gestations (66 singleton
and one twin gestation). Fourteen women had
more than one subsequent pregnancy. The live
birth rate was 85.1% (57/67) with 10 pregnancies
failures: seven in the first and second trimesters,
one late fetal death and two medical terminations
of pregnancy (one APS related and one due to fe-
tal cardiac malformation). The only patient, who
started late pregnancy surveillance and carried al-
ready a 12th week gestation in the first visit to the
clinic, resulted in a 2nd trimester miscarriage (Ta-
ble II).
The group of patients who were positive for both
LA and aCL had the worst pregnancy outcome with
a success rate of 75.7% against 96.71% if only one
antibody was present (p<0.05). A past thrombotic
event was also a strong risk factor for pregnancy
failure, odds ratio 5.98 95% CI (1.17 – 33.98).
In pregnancies that progressed beyond 20 weeks
there were 13 hypertensive complications: two
pregnancy induced hypertensions, 4 superimpo-
sed preeclampsia, 2 mild and two severe pre-
eclampsia and 3 HELLP syndromes. The most se-
rious situations (2 severe preeclampsias and three
tein I (all positive for either aCL or LA).
Women with systemic lupus erythematosus or
other autoimmune diseases were excluded. 
All patients were managed by a multidiscipli-
nary support team, which included an obstetri-
cian and an internist. Most of the patients 43/51
(84.3 %) had a preconcepcional consultation. One
woman carried already a 2nd trimester pregnancy
in the first visit to our clinic. Although the fre-
quency of the surveillance was individualized, wo-
men attended for antenatal care as having high-
risk pregnancies and, both the mother and the fe-
tus, were closely monitored at least monthly until
32th week and weekly thereafter. 
All patients except that one presenting with an
ongoing 2nd trimester pregnancy started low dose
aspirin (100 mg daily) as soon as they had a posi-
tive urinary pregnancy test. Vaginal ultrasound
scans were performed from 6 weeks of ame-
norrhoea. When fetal heart activity was seen on ul-
trasonography, low molecular weight heparin
(LMWH) was added. Treatment with aspirin was
stopped one week before delivery, to allow for epi-
dural analgesy. LMWH was continued until onset
of labor or the day before a planned delivery and
resumed for 4 to 6 weeks. Women with previous ve-
nous thrombotic events, and on oral anticoagula-
tion, started LMWH when an urinary pregnancy
tested positive and restarted postpartum warfarin
as soon as possible. Anti-Xa activity was not mea-
sured routinely. 
Uterine artery Doppler waveform studies were
perform at 22 - 24 weeks’ gestation in 30 gesta-
tions; serial growth scans were accomplished in all
pregnancies from 24 week´s until delivery, with in-
creased fetal surveillance if FGR was suspected.
The timing of delivery was assessed individually.
In uncomplicated cases, induction of labor was not
recommended until 40 weeks’ gestation. Cesarean
sections were performed for obstetric reasons. 
After delivery, patients were counseled about
the important risk of developing thrombotic com-
plications associated with APS and were referred to
our family planning clinic. Estrogen containing
Table I. Previous obstetric history
Pregnancy loss Pre-embryonic Embryonic Fetal Stillbirth
Gestational age < 6 w 6-9 w 10-22 w >22 w
Nº losses 6 44 34 16
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HELLP) occurred before 34 weeks of gestation. One
woman developed HELLP syndrome at 18’ weeks
of gestation with a prolonged stay in an intensive
care unit.
There were 9 cases of fetal growth restriction
(FGR) with four fetal deaths: three before 24 weeks’
gestation and one 31 weeks` stillbirth. Two of the-
se FGR gestations were complicated by placental
abruption at 28 and 32 weeks’ (one HELLP syndro-
me), both with living children.
46.7 % (14/30) of women had Doppler uterine
artery protodiastolic notches. This finding was as-
sociated with prematurity (p< 0.01) and FGR
(p<0.05). Patients with FGR were 2.6 times more
likely to have an abnormal uterine artery Doppler
profile than patients without FGR (likelihood ratio
of 2.6). The small number of cases does not permit
the 95% CI calculation.
54.4% of the patients delivered by caesarean
section. The major indication was fetal distress
(35.5 %), followed by failed induction of labor
(21.6%).
There were 58 live newborns (one twin gesta-
tion). The probability of having a live baby was
85.1%, a figure significantly greater than that
(13.79%) observed before therapy (p<0.001). Mean
(± SD) birthweight was 2837 ± 812 g (min 460
max 4050) at mean gestational age 37 ± 3.3 weeks
(min 24 max 40). Mean birthweight percentile was
42.8 ± 23.5.
Twelve of the successful pregnancies (21 %) re-
sulted in a preterm delivery. This was due to spon-
taneous labour in four cases (one twin pregnancy).
Fetal growth restriction was the indication for ter-
mination of pregnancy in 4 patients, HELLP
syndrome in two and placental abruption in ano-
ther two cases. One third (4/12) of these mothers
had history of previous late fetal deaths and eight
(67%), of previous thrombotic events. Most of them
(83%) had pathological uterine Doppler at 22-24
weeks.
All babies were examined by a paediatrician
shortly after delivery. Ten were admitted to the neo-
natal intensive care unit (NICU). Only one neona-
te weighed 460 g, who was delivered by caesarian
section at 24 week’ gestation for HELLP syndrome,
required a more aggressive management due to
bronchopulmonar dysplasia and retinopathy of
prematurity grade II. This neonate responded well
in the NICU and was discharged 154 days after.
The other 9 babies were admitted to the unit with
mild prematurity complications. Four of them re-
quired a short time of ventilatory support. There
were no cases of neonatal thrombosis, intraventri-
cular hemorrhage or neonatal deaths. 
No woman developed a thromboembolic com-
plication during pregnancy or puerperium. There
were no maternal deaths (Table III).
Discussion
In the last three decades many efforts have been
made to identify the best way to monitor and to
manage pregnancies associated to APS. Nowadays,
with an appropriate treatment, a close obstetric
monitoring and careful delivery timing, APS pa-
tients can reach live birth rates higher than 70%.18
Table II. Pregnancy outcome
Pregnancy losses Living children (weeks)
Loss Type 1st trim 2nd trim Stillbirth TOP* 24 - 27 28 - 31 32 - 33 34-36 >37
n 3 4 1 2* 1 4 3 5§ 45
Total 10 58
*Two Terminations of Pregnancy: One severe hypoplastic left heart syndrome (HLHS) diagnosed at 20th week. One severe FGR diagnosed at 22th week
§One twin pregnancy
Table III. Outcome data (67 pregnancies)
Live births (n) 58 * (85.1%)
Mean Gestational age at birth 37.05 ± 3.3 W
Mean Birth weight 2837 ± 812 g
Pregnancy loss (n) 10 (14.9 %)
Preterm birth (n) 12 (21%)
FGR (n) 9 (15.5%)
Pregnancy-related hypertension (n) 13 (21.3%)
Caesarean section (n) 31 (54.4%)
*One twin pregnancy
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Success, defined as fetal survival, was reached in
85.1% of our patients, similar to reported by 
others in treated women with PAPS.19-21
Positivity for both LA and aCL and a previous
thrombotic history were the two main predictors
for bad outcome. 
The association between severe preeclampsia
and APS has long been described in several studies.
Since the statement of the clinical criteria for an-
tiphospholipid syndrome in 1999,1 several publica-
tions emerged supporting or refuting an associa-
tion between these antibodies and preeclam-
psia.14,23-25 In a recent study including 406 women
with severe preeclampsia, the prevalence of anti-
phospholipid antibodies (13%) was significantly
higher than in controls (3.7%).26 In our cohort,
21.3% of pregnancies (13/61) that progressed be-
yond 20 weeks were complicated by hypertensive
disorders (pre-eclampsia, superimposed pre-
eclampsia or HELLP syndrome). This was a very
high prevalence compared to the overall hospital
rate (6%).27 Elevated preeclampsia prevalence
(18%) was also found by Lima et al, in sixty patients
with primary and secondary APS,20 and by Tincani
et al (11.6%) in 58 patients with PAPS.22
APS patients seem to be more susceptible to ear-
ly-onset HELLP syndrome. This complication can
occur as early as 15–20 weeks’ gestation and might
progress rapidly, often necessitating termination of
the pregnancy.28,29 In our series, all the four cases
of HELLP syndrome occurred before the 32th week
of gestation. In one case it developed at 18th weeks,
and was a life-threatening condition. In a recent
study, HELLP developed in 44% of the cases during
the second trimester and 12.5% at 18–20 weeks.28
Fetal growth restriction complicated five (10.6%)
of our successful pregnancies (5/47), similar to tho-
se found by Stone et al (13.3%)21 and Cervera & Ba-
lasch (12.8%).19
Uterine artery Doppler blood flow analysis
provides a noninvasive indirect method of scree-
ning women with risk for uteroplacental insuffi-
ciency.30-32 Various studies have been performed to
validate the predictive value of uterine artery Dop-
pler waveform pattern in relation to pregnancy
outcome in APS patients.21,31,33 In our data, the exis-
tence of protodiastolic uterine artery notches was
also associated with fetal growth restriction and
preterm delivery.
The cesarean section rate in this cohort was very
high (54.4%), compared to the overall rate of our
hospital (30%). However, high cesarean section ra-
tes were described as well by other authors, pro-
bably related to women’s past obstetric history. Sto-
ne et al in a prospective study with 33 PAPS gesta-
tions reported a 59% C-section rate.21 In the study
by Backos et al, 46% of the women also delivered
by caesarean.34
In most studies, a significant number of APS
pregnancies were associated with premature de-
livery. In a controlled evaluation of 69 gestations in
58 PAPS patients, Tincani et al found an 18.8% ove-
rall prevalence of prematurity.22 Cervera & Balasch
in a series of 77 treated pregnancies in 56 women
with primary or secondary APS, found a similar
rate of premature deliveries (21.4%).19 Rai et al re-
ported a 24% preterm rate.4 In our population, the
main problem was also prematurity which occur-
red in up to 21 % of the successful pregnancies. 
Conclusions
Antiphospholipid syndrome is frequently associa-
ted with complications during pregnancy. Despi-
te a high incidence of obstetric complications, such
as preeclampsia, FGR and prematurity, early treat-
ment with aspirin and LMWH combined with ca-
reful maternal-fetal monitoring was, in our popu-
lation, associated with a high chance of a live new-
born. An accurate preconceptional counseling and
a close collaboration between obstetricians and
other specialities was essential for this outcome.
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